Introduction {#s1}
============

Colorectal cancer is the third most common malignancy worldwide, and one of the leading causes of cancer-related deaths [@pone.0080337-Siegel1]. An increasing trend in the incidence of this carcinoma has been noticed in the Asian nations. Despite recent therapeutic advances, its 5-year survival rate is still pessimistic due to its recurrence and drug resistance [@pone.0080337-Jemal1]. Growing evidence suggests that hypoxia plays a pivotal role in disease progression and therapy resistance in most solid tumors, including colorectal cancer [@pone.0080337-Griffiths1], [@pone.0080337-Baba1]. Rapid oxygen consumption and aberrant tumor angiogenesis and blood flow result in a hypoxic tumor environment. Owing to the fundamental importance of oxygen for metabolism and survival, cells have evolved intricate response mechanisms to respond to hypoxia. The most important regulators mediating the primary transcriptional responses to hypoxic stress are hypoxia-inducible factors (HIFs). Given that hypoxia promotes tumor progression and therapy resistance, HIFs are expected to be useful biomarkers associated with progress disease and poor prognosis in CRC. Increased expression of HIFs has also been observed in a broad range of human cancer cell types, and has been associated with poor prognosis in many cases [@pone.0080337-Yoshimura1], but the prognostic value of HIFs for CRC patients is inconclusive.

HIFs are heterodimers composed of an inducible a-subunit (HIF-1α, HIF-2α or HIF-3α), and a constitutive HIF-1β subunit (also known as aryl hydrocarbon receptor nuclear translocator or ARNT), which together form the HIF-1, HIF-2 and HIF-3 transcriptional complexes, respectively. Of the three HIF family members, HIF-1 and HIF-2 are the most well-characterized. HIF-1α and HIF-2α are usually detected to measure tumor oxygen levels because the HIF-1β subunit is constitutive. HIF-1α and HIF-2α have 48% amino acid sequence identity and similar protein structures, but distinct target genes and mechanisms of regulation. HIF-1α preferentially induces glycolytic pathway, whereas HIF-2α regulates genes involved in tumor growth, cell cycle and maintaining stem cell pluripotency [@pone.0080337-Hu1]. Thus, HIF1α and HIF2α can promote highly divergent, even opposing, outcomes, which results in distinct clinicopathologic features and prognosis. Multiple xenograft tumour models also support the hypothesis that HIF1α and HIF2α play different roles in tumor progression by regulating both shared and unique target genes [@pone.0080337-Mazumdar1]. However, clinicopathologic and prognostic differences of HIF1α and HIF2α in CRC were rarely compared in recent studies.

Therefore, we made a meta-analysis from eligible studies to investigate the relationship between HIF expression and prognosis of CRC patients. Meanwhile, we performed a subgroup analysis to assess the roles of HIF-1α and HIF-2α in clinicopathologic features and prognosis of CRC.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2a}
--------------------------------------------------

We searched literature from PubMed, WanFang and Web of Science databases using the terms: "HIF", "colorectal neoplasms", "colorectal Cancer", "colon cancer" "rectal cancer", "prognosis" with all possible combinations. Bibliographies, review articles and other pertinent studies were searched manually for additional eligible studies.

The inclusion criteria for eligibility of a study in the meta-analysis were as follows: (1) evaluating HIF expression in the human CRC tissues; (2) assessing the relationships between HIFs expression with CRC clinicopathologic features or prognosis; (3) articles written in English or Chinese; (4) sufficient information provided to estimate hazard ratio (HR) about overall survival (OS) or disease free survival (DFS), or to estimate odds ratio (OR) about clinicopathologic features. In addition, letters, reviews, conference abstracts, and case reports were not in the scope of our analysis because of the limited data. Overlapping articles were also excluded from this meta-analysis, only the most recent or the most complete study was involved in the analysis.

Data extraction and management {#s2b}
------------------------------

Two investigators (Xin He and Wenjie Xia) reviewed each eligible study independently and extracted data from all the publications meeting the inclusion criteria. Controversial problems were arbitrated by the third investigator (Jinhong Xu). The following information was collected from each study: the first author\'s name, year of publication, country of origin, number of patients, gender of patients, HIF isoforms, source and dilution of antibody, cut-off value, tumor characteristics, condition of adjuvant therapy and survival data.

Methodological assessment {#s2c}
-------------------------

Newcastle--Ottawa quality assessment scale (NOS) was used to assess the quality of each study [@pone.0080337-Stang1]. The score assessed eight items of methodology, categorized into three dimensions including selection, comparability, and outcome. A maximum of 1 score was awarded for each item with the exception of the item related to comparability that allowed the assignment of two scores. A total of 0 and 9 scores were respectively designated as lowest and highest quality, and the studies with 6 scores or more were graded as the high quality ones in the scale. The scores provided by two researchers were compared and a consensus value for each item was achieved.

Statistical methods {#s2d}
-------------------

For the pooled analysis of the impact of HIF expression on survival outcome, HRs and its 95% CI were used. If these statistical variables were described in a literature, we pooled it directly; otherwise, they were calculated from available numerical data in the articles according to the methods described by Parmar [@pone.0080337-Parmar1]. In brief, if the trials offered the data such as log-rank test p values, number of total events. The number of aberrant HIF expression and number of preserved HIF expression were extracted to allow estimation of the HR and its 95% CI. If only Kaplan Meier graphs were published, Kaplan-Meier curves were read by Engauge Digitizer version4.1 (<http://digitizer.sourceforge.net/>). Time-to-event data from the Kaplan--Meier curves was extracted and HR and its 95% CI were calculated via SPSS16.0. Odds ratios (ORs) and their 95%CIs were combined to evaluate the association between HIF expression and clinicopathological factors, such as differentiation grade, Dukes\' stages, depth of invasion, lymphnode status and metastasis. An observed HR\>1 implies worse survival for the group with overexpressed/negative HIF expression. An observed OR\<1 implies unfavorable parameters for the group with overexpressed/negative HIF expression. The impact of overexpressed/negative HIF expression on survival or clinicopathological factors was considered to be statistically significant if the 95%CI did not overlap with 1. Heterogeneity in between-study was assessed by Chi- square based Q statistical test [@pone.0080337-Handoll1]. And the I^2^ statistic to quantify the proportion of the total variation, which is due to inter-study heterogeneity rather than sampling error and is measured from 0% to 100% [@pone.0080337-Ioannidis1]. Higher values indicate a greater degree of heterogeneity. When the studies were found to be homogeneous(with *P*\>0.10 for the Q test), the pooled ORs and HRs estimate of each study were calculated by the fixed-effects model (the Mantel-Haenszel method) [@pone.0080337-Mantel1]. Otherwise, we chose the random-effects model (the DerSimonian and Laird method) [@pone.0080337-Higgins1]. We assessed the possibility of publication bias by visually assessing a funnel plot for asymmetry and by quantitatively performing Egger\'s test. Publication bias was indicated when p value of Egger\'s test \<0.05. The meta-analysis was performed using STATA version 12.0 software (Stata Corporation, Collage Station, Texas, USA). All the P values were for a two-side test and considered statistically significant when p\<0.05.

Results {#s3}
=======

Description of studies {#s3a}
----------------------

As shown in [**Figure 1**](#pone-0080337-g001){ref-type="fig"}, 227 published records were identified from a search of the above databases using the search strategy as described above. After exclusion of the studies that were out of the scope of our systematic review, a total of 23 eligible studies were included in the final meta-analysis [@pone.0080337-Baba1], [@pone.0080337-Yoshimura1], [@pone.0080337-Xie1]--[@pone.0080337-Mohammed1]. Of these 23 publications, 20 studies assessed the relationships between HIF-1 expression with CRC clinicopathologic features or prognosis, while 6 studies evaluated the association of HIF-2 expression and CRC pathological features or prognosis. The clinical features of these 23 included studies were summarized in [**Table 1**](#pone-0080337-t001){ref-type="table"}. These studies were published from 2003 to 2013, and total 2984 CRC patients were enrolled. Sample sizes ranged from 30 to 731 patients (mean 130). 14 of these studies enrolled less than 100 patients and 9 studies included more than 100 patients. 6 of these studies evaluated patients from China, 5 from Japan, 3 from England, others from America, Korea, Finland, Germany, Austrialia, Holand and Greece. 19 of these studies got 6 scores or more in methodological assessment, which meant they had high qualities.

![Flow diagram of study selection procedure.](pone.0080337.g001){#pone-0080337-g001}

10.1371/journal.pone.0080337.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0080337.t001){#pone-0080337-t001-1}

  First author      Year      Country      HIF isoforms   Number of total patient(positive)   Expression location   Method        Antibody source        Antibody dilution                      Definition of HIF positive                                  HR estimation               Quality score
  ---------------- ------ --------------- -------------- ----------------------------------- --------------------- -------- --------------------------- ------------------- ------------------------------------------------------------------ --------------------------------------- ---------------
  Xie               2012       China          HIF-1α                   93(46)                       C and N          IHC            Santa Cruz                 1∶100         Multiplying the intensitys core by expressions core≥median value                    NA                           8
  Korkeila          2011      Finland         HIF-1α                   168(68)                         N             IHC                BD                     1∶100                         Weak,moderate or strong staining                                HR for DFS                       7
  Shioya            2011       Japan          HIF-1α                   50(21)                          N             IHC            Neomarkers                1∶20000                                      40%                                  HR for OS and survival curves for DFS         8
  Havelund          2011      Denmark         HIF-1α                   86(39)                          N             IHC                BD                     1∶75                 Summing the intensitys core and expressions core≥3                 Survival curves for OS                 7
  Saigusa           2011       Japan          HIF-1α                   52(NA)                         NA            RT-PCR              NA                      NA                           0.0212 for PFS and 0.1274 for OS                             HR for OS and DFS                   7
  Mohammed          2011       Spain          HIF-2α                   154(NA)                        NA            RT-PCR              NA                      NA                                          NA                                                   NA                           6
  Kwon              2010       Korea          HIF-1α                  311(196)                         N             IHC               Novus                   1∶50                                        10%                                            HR for OS and DFS                   7
  Wu                2010       China          HIF-1α                   68(30)                       C and N          IHC               Abcam                   1∶200              Multiplying the intensitys core by expressions core≥5                          NA                           6
  Zheng             2010       China          HIF-1α                   62(39)                       C and N          IHC              Boster                   1∶400                Summing the intensitys core and expressions core≥5                           NA                           5
  Baba              2010   United States      HIF-1α                  731(142)                         C             IHC            Santa Cruz                 1∶500                  Moderate staining\>50% or Any strong staining                           HR for OS                       7
                                              HIF-2α                  695(322)                         C             IHC            Santa Cruz                 1∶250                            Weak to strong expression.                                    HR for OS                
  Toiyama           2010      England         HIF-1α                   40(NA)                         NA            RT-PCR              NA                      NA                                        0.3649                                             HR for DFS                       5
  Gao               2009       China          HIF-1α                   71(39)                       C and N          IHC               Zymed                   1∶50                                    Any staining                                           HR for OS                       8
  Jubb              2009    Austrialia        HIF-2α                   155(60)                         N             IHC                BD                      NA                                     Any staining                                           HR for OS                       6
  Rajaganeshan      2009      England         HIF-1α                   55(25)                       C or N           IHC               Abcam                   1∶100            \>10% in nuclear or distinct, Strong staining in cytoplasm                   HR for DFS                       4
  Schmitz           2009      Germany         HIF-1α                   129(34)                         N             IHC     Transduction Laboratories         1∶10                                    Any staining                                              NA                           8
  Rasheed           2009      England         HIF-1α                   90(48)                       C and N          IHC               Novus                   1∶500                                        NA                                               HR for DFS                       7
                                              HIF-2α                   90(58)                       C and N          IHC               Novus                   1∶100                                        NA                                                   NA                    
  Cleven            2007      Holand          HIF-2α                  133(110)                         N             IHC                BD                     1∶120                                        5%                                                HR for OS                       4
  Lu                2006       China          HIF-1α                   30(19)                          N             IHC                NA                     1∶200                                       10%                                         Survival curves for OS                 7
  Theodoropoulos    2006      Greece          HIF-1α                   92(44)                          N             IHC            Stress Gene               1∶1200                           Moderate or strong staining                                HR for OS and DFS                   7
  Yoshimura         2004       Japan          HIF-1α                   87(39)                          N             IHC               Novus                  1∶1000                                        5%                                         Survival curves for OS                 6
                                              HIF-2α                   87(26)                          N             IHC               Novus                  1∶1000                                        5%                                         Survival curves for OS          
  Kuwai             2003       Japan          HIF-1α                   139(81)                      C and N          IHC               Dako                   1∶1000                                      9.60%                                                  NA                           6
  Shimomura         2013       Japan          HIF-1α                   64(20)                          C             IHC               Novus                   1∶50                     Sum the intensity and percentage scores≥6                      Survival curves for OS                 7
  Yu                2012       China          HIF-1α                   124(67)                         C             IHC               Abcam                   1∶100                                       10%                                         Survival curves for OS                 6

**NA, not available; HR, hazard ratio; OS, overall survival; DFS, disease free survival**; **IHC**, **immunohistochemistry**; C, cytoplasm; N, nucleus.

Impact of HIFs expression on overall survival and disease free survival of colorectal cancer {#s3b}
--------------------------------------------------------------------------------------------

The meta-analysis was performed on 15 studies assessing the association of HIFs expression with OS. The pooled HR was 2.06 (95%CI 1.55--2.74; I^2^ 69.1%) ([**Figure 2A**](#pone-0080337-g002){ref-type="fig"}). Nine studies evaluating the correlation of HIFs expression with DFS were all about HIF-1α. The pooled HR was 2.84 (95%CI 1.87--4.31; I^2^ 41%) ([**Figure 2B**](#pone-0080337-g002){ref-type="fig"}). It suggested that overexpressed HIF was significantly associated with increase of mortality risk. In addition, sensitive analysis was performed. We removed one study at a time and evaluated the rest, pooled HR of HIFs overexpression on OS ranged from 1.98(95% CI: 1.5--2.61) to 2.28(95% CI: 1.74--2.98) ([**Table 2**](#pone-0080337-t002){ref-type="table"}), and combined HR of HIFs overexpression on DFS ranged from 2.34(95% CI: 1.68--3.26)to 3.22(95% CI: 2.08--4.99) ([**Table 3**](#pone-0080337-t003){ref-type="table"}). We also performed subgroup analysis about association of HIFs expression with OS by HIF isoforms, the results showed that both HIF-1α and HIF-2α were associated with worse prognosis. The pooled HR was 2.01 (95% CI: 1.55--2.6, I^2^ 33.1%) and 2.07(95% CI: 1.01--4.26, I^2^ 86.1%) respectively ([**Figure 2A**](#pone-0080337-g002){ref-type="fig"}). Subgroup analysis about association of different subcellular localization of HIFs expression with OS was performed, and the results showed that the correlation was not changed no matter where HIF located in (nucleus or cytoplasm). The pooled HR was 2.456 (95% CI: 1.694--3.561, I^2^ 49.2%) and 2.049(95% CI: 1.519--2.764, I^2^ 0%), respectively ([**Figure 3**](#pone-0080337-g003){ref-type="fig"}).

![Forrest plot of Hazard ratio (HR) for the association of different HIF isoforms expression with overall survival (OS) and disease free survival (DFS).\
**A.** HRs with corresponding 95% CIs of the HIFs expression with OS. **B.** HRs with corresponding 95% CIs of the HIFs expression with DFS. HR\>1 implied worse survival for the group with increased HIFs/negative expression and overexpressed HIFs was significantly with the worse prognosis of CRC patients.](pone.0080337.g002){#pone-0080337-g002}

![Forrest plot of Hazard ratio (HR) for the association of HIF in different subcellular localization with overall survival (OS).](pone.0080337.g003){#pone-0080337-g003}

10.1371/journal.pone.0080337.t002

###### HRs (95% CI) of sensitivity analysis for HIFs overexpression on OS.

![](pone.0080337.t002){#pone-0080337-t002-2}

  Study omitted            Estimated HR   low value of 95%CI   High value of 95%CI
  ----------------------- -------------- -------------------- ---------------------
  Korkeila (2011)            3.08576           2.080869             4.575933
  Shioya (2011)              2.716886          1.716758             4.299657
  Kwon (2010)                3.219644          2.075922             4.993494
  Saigusa (2011)             2.852396          1.829702             4.446713
  Toiyama (2010)             2.839389          1.815004             4.441936
  Rajaganeshan (2009)        2.338718          1.678648             3.258336
  Rasheed (2009)             2.684669          1.706306             4.224007
  Theodoropoulos (2006)      2.776092          1.734063             4.444295
  Shimomura (2013)           3.028906          1.852393              4.95266
  Combined                  2.8408349         1.8734429             4.3077604

10.1371/journal.pone.0080337.t003

###### HRs (95% CI) of sensitivity analysis for HIFs overexpression on DFS.

![](pone.0080337.t003){#pone-0080337-t003-3}

  Study omitted            Estimated HR   low value of 95%CI   High value of 95%CI
  ----------------------- -------------- -------------------- ---------------------
  Shioya (2011)             2.0867274          1.567879             2.7772751
  Havelund (2011)           2.2600963         1.7024611             3.0003829
  Kwon (2010)               2.1164002         1.5588678             2.8733358
  Saigusa (2011)            2.0795095         1.5696353             2.7550092
  Baba (2010)               2.2764547         1.7367126             2.9839401
  Gao (2009)                2.1033344         1.5671818             2.8229115
  Lu (2006)                 2.0664124         1.5748442             2.7114177
  Theodoropoulos (2006)     2.0455844          1.541568             2.7143891
  Yoshimura (2004)          1.9817994         1.5027167             2.6136189
  Shimomura (2013)          2.2203045         1.6552455              2.97826
  Yu (2012)                 2.1814032          1.602671             2.9691179
  Jubb (2009)               2.2353566         1.6377747             3.0509808
  Cleven (2007)             2.0521758          1.554372             2.7094064
  Combined                   2.127789         1.6131618             2.8065913

Moreover, further subgroup analysis on HIF-1α was performed by study location, number of patients, antibody dilution, cut-off value. Subgroup analysis indicated a significant relation between HIF-1α overexpression and OS was exhibited in Asian countries (HR 2.3, 95% CI: 1.74--3.01, I^2^ 0%). Other factors comprising number of patients, antibody dilution and cut-off value did not alter the significant OS of overexpressed HIF-1α ([**Table 4**](#pone-0080337-t004){ref-type="table"}).

10.1371/journal.pone.0080337.t004

###### Stratified analysis of pooled hazard ratios for colorectal cancer patients with overexpressed HIF-1α.

![](pone.0080337.t004){#pone-0080337-t004-4}

                                                               Heterogeneity          
  --------------------- --- ------ ------------------ ------- --------------- ------- -----
  Study location                                                                      
  Asia                   8   789    2.3(1.74--3.01)    0.000         0         0.598   FEM
  Europe                 2   178    1.96(0.64--6.03)   0.239       77.7        0.034   REM
  Nubmer of patients                                                                  
  \>100                  3   1166   1.67(1.34--2.07)   0.000       23.3        0.272   FEM
  \<100                  8   532    2.11(1.54--2.88)   0.000       35.7        0.144   FEM
  Cut off value                                                                       
  Percentage             5   602    2.41(1.72--3.38)   0.000         0         0.621   FEM
  Staining               2   163    3.12(1.69--5.75)   0.000         0         0.624   FEM
  Percentage+staining    3   881    1.43(1.14--1.79)   0.002         0         0.727   FEM
  Dilution                                                                            
  ≤1∶500                 6   686    1.85(1.39--2.46)   0.000       29.1        0.217   REM
  \>1∶500                4   960    1.73(1.37--2.17)   0.000       52.2        0.099   FEM

REM, random-effectsmodel; FEM, fixed-effectsmodel; HR, hazard ratio; CI, confidenceinterval.

Correlation of HIFs expression with clinicopathological parameters {#s3c}
------------------------------------------------------------------

The meta-analysis was also assessed the correlation between HIF-1α expression and clinicopathological characteristics of CRC. As shown in [**Table 5**](#pone-0080337-t005){ref-type="table"}, overexpression of HIF-1α was significantly associated with Dukes\' stages (OR 0.39, 95% CI: 0.17--0.89), UICC stages (OR 0.42 95% CI: 0.3--0.59), depth of invasion (OR 0.71, 95% CI: 0.51--0.99), lymphnode status (OR 0.49, 95% CI: 0.32--0.73) and metastasis (OR 0.29, 95% CI: 0.11--0.81). Furthermore, there was no significant association between HIF-1α expression with grade of differentiation. The pooled OR was 0.97 (95% CI: 0.67--1.39). ([**Figure 4**](#pone-0080337-g004){ref-type="fig"}).

![Forrest plot of odds ratios (ORs) for the association of HIF-1α expression with clinicopathological features.\
**A.** ORs with corresponding 95% CIs of the HIF-1α expression with Dukes\' stages. OR\<1 suggested that unfavorable parameters for the group with increased HIF-1α expression/negative. Overexpressed HIF-1α was associated with advanced Dukes\' stage of CRC. **B.** ORs with corresponding 95% CIs of the HIF-1α overexpression with UICC stage. OR\<1 suggested that unfavorable parameters for the group with increased HIF-1α expression/negative and HIF-1α overexpression was associated with advanced stage of CRC. **C.** ORs with corresponding 95% CIs of the HIF-1α overexpression with depth of invasion. **D.** ORs with corresponding 95% CIs of the HIF-1α overexpression with lymphnode metastasis.](pone.0080337.g004){#pone-0080337-g004}

10.1371/journal.pone.0080337.t005

###### HIF-1α and HIF-2α expression and clinicopathological features for colorectal cancer.

![](pone.0080337.t005){#pone-0080337-t005-5}

                                                                     Heterogeneity          
  ----------------------- ---- ------ --------------------- ------- --------------- ------- -----
  HIF-1α                                                                                    
  Differentiation grade    15   2226    0.97 (0.67--1.39)    0.864       39.2        0.06    REM
  Dukes\' stages           5    408     0.39(0.17--0.89)     0.025       66.2        0.019   REM
  Lymphnode status         15   1490    0.49(0.32--0.73)     0.001       62.4        0.001   REM
  Metastasis               5    480     0.29(0.11--0.81)     0.018       52.8        0.076   REM
  UICC stage               9    1733     0.42(0.3--0.59)     0.000       53.2        0.029   REM
  Depth of invasion        9    1016    0.71(0.51--0.99)     0.045       0.00        0.851   FEM
  HIF-2α                                                                                    
  Differentiation grade    2    782    0.484(0.289--0.812)   0.006        58         0.123   FEM
  Dukes\' stages           2    177     0.9(0.197--4.168)     0.9         82         0.019   REM
  Lymphnode status         3    329     0.95(0.418--2.16)    0.904       63.7        0.064   REM
  Depth of invasion        2    177    0.379(0.038--3.798)   0.409       83.4        0.014   REM

REM, random-effects model; FEM, fixed-effects model; OR, odds ratio; CI, confidence interval.

In addition, we evaluated the correlation between HIF-2α overexpression with clinicopathological characteristics of CRC. The result showed that overexpression of HIF-2α was significantly associated with grade of differentiation (OR 0.48, 95% CI: 0.29--0.81). There was no significant association between HIF-2α expression with Dukes\' stages, depth of invasion and lymphnode status. The pooled OR was 0.91(95% CI: 0.20--4.17), 0.38 (95% CI: 0.04--3.80), and 0.95 (95% CI: 0.428--2.16), respectively ([**Table 5**](#pone-0080337-t005){ref-type="table"}).

Publication bias {#s3d}
----------------

Egger\'s test indicated that there was no evidence of significant publication bias after assessing the funnel plot (**[Figure S1](#pone.0080337.s001){ref-type="supplementary-material"}--[S3](#pone.0080337.s003){ref-type="supplementary-material"}**) for the studies included in our meta-analysis.

Discussion {#s4}
==========

Hypoxia has been recognized as a common feature of solid tumors and a negative prognostic factor for response to treatment and survival of cancer patients. In 1993, Höckel reported that cervix cancer patients with hypoxic tumors (median pO~2~\<10 mmHg) had a significantly lower overall and recurrence-free survival [@pone.0080337-Hockel1]. Since then, hypoxia has been found to indicate a highly aggressive disease phenotype associated with poor prognosis in many cancers, including brain, breast, prostate, pancreas, cervix, bladder and ovary [@pone.0080337-Birner1]--[@pone.0080337-Theodoropoulos2]. HIFs are the best characterized markers mediating transcriptional responses to hypoxic stress and expected to be unfavorable prognostic indicators. Hypoxia and consequently HIF activation is regarded as an important stimulus of CRC angiogenesis. HIF binds to the HRE in the VEGF promoter region, leading to up- regulation of VEGF transcription and the formation of new blood vessels [@pone.0080337-Sutter1]. Surprisingly, both HIF-1 and HIF-2 can function as tumor suppressors in certain cancers [@pone.0080337-Lidgren1]. Many studies were also performed to assess the prognostic value of HIF for CRC patients, but the conclusions were also inconclusive. On the other hand, HIF-1 and HIF-2 have distinct target genes, but few studies compared the clinicopathologic and prognostic differences between HIF-1 and HIF-2.

This meta-analysis aimed to examine the association between HIFs expression and the prognosis of CRC patients, and assess the roles of HIF-1α and HIF-2α in clinicopathologic features. Our analysis combined the outcomes of 23 studies comprising 2984 CRC patients, indicating that overexpressed HIF was significantly associated with increase of mortality risk, including OS (2.06 95%CI 1.55--2.74; Z = 4.95; P = 0.000) and DFS (2.84,, 95%CI 1.87--4.31; Z = 4.92; P = 0.000). Additionally, the results of sensitivity analysis showed that the association was not changed after removing any study. Subgroup analysis revealed that both overexpressed HIF-1α and HIF-2α were associated with worse prognosis in CRC. On the basis of different HIF isoforms, further subgroup analysis was performed by study location, number of patients, antibody dilution, cut-off value. HIF-1α overexpression was significantly associated with poor OS in Asian countries (HR 2.3, 95% CI: 1.74--3.01, Z = 5.76, P = 0.000), while not in European or other countries. It indicated that HIF-1α overexpression seemed to be associated with disease progress and unfavorable prognosis in Asian CRC patients. Other factors did not alter the significant OS of overexpressed HIF-1α. In addition, significant correlations were observed between HIF-1α overexpression with clinicopathological features including Dukes\' stages, UICC stages, depth of invasion, lymphnode status and metastasis. Our results concurred with previous study that HIF-1α expression had a significant inverse correlation in T1 and T2 CRC. On the other hand, overexpression of HIF-2α was significantly associated with grade of differentiation. Thus, HIF-1 and HIF-2 indicate distinct clinicopathologic features.

In this meta-analysis, we had dealt with highly significant heterogeneity among the 23 studies. Although we used random effects models to analyze the data, it did not identify the source of heterogeneity. Thus, we performed stratified analysis according to study location, number of patients, cut-off value. When the analysis on OS was performed without consideration of other factors, heterogeneity was detected (I^2^ 69.1% P = 0.000). While when the studies included were classified into three groups according to evaluation criterion (percentage, staining and percentage plus staining), the heterogeneity was not detected (I^2^ 0% P = 0.621, I^2^ 0% P = 0.624, I^2^ 0% P = 0.727). Therefore, the heterogeneity in this study could be explained by the evaluation standards. Meanwhile, there were some limitations in this meta-analysis. First, the study included in our meta-analysis was restricted only to articles published in English or Chinese, which probably provided additional bias. Second, HRs calculated from data or extracted from survival curves might be less reliable than direct analysis of variance. Third, the sample size in European studies was not big enough so that the difference of HIF-1expression on survival was not significant.

In summary, we showed that both overexpressed HIF-1α and HIF-2α were significantly associated with worse prognosis in CRC. Subgroup analysis indicated that HIF-1α overexpression was associated with progress disease and unfavorable prognosis in Asian CRC patients. Significant correlations were observed between HIF-1α overexpression with Dukes\' stages, UICC stages, depth of invasion, lymphnode status and metastasis, but there was no significant association between overexpressed HIF-1α with grade of differentiation. While overexpressed HIF-2α was only associated with differentiation. Large, well-designed prospective studies are required to investigate the precise prognostic significance and clinicopathologic differences of HIFs expression.

Supporting Information {#s5}
======================
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**Egger\'s publication bias plot showed no publication bias for studies regarding overexpressed HIF-1α and overall survival (OS) in the meta-analysis: the relationship between the effect size of individual studies (HR, vertical axis) and the precision of the study estimate (standard error, horizontal axis).**
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**Egger\'s publication bias plot showed no publication bias for studies regarding overexpressed HIF-1α and disease free survival (DFS) in the meta-analysis.**

(TIF)
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**Egger\'s publication bias plot showed no publication bias for studies regarding overexpressed HIF-2α and overall survival (OS) in the meta-analysis.**

(TIF)
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